The Centre for Pharmaceutical Oncology (CPO) aims to bridge the gap between fundamental discoveries in cancer biology and the development of new diagnostics and therapeutics for cancer and their advancement to first-in-humans Phase I/II clinical trials.
CPO Members are conducting research that focuses on the development of new diagnostics and therapeutics for cancer with the aim to advance these to first-in-humans clinical trials and ultimately effective introduction into the health care system. The current research priorities of the Centre include breast cancer, ovarian cancer, and pancreatic cancer.
The CPO is leading the development of undergraduate and graduate education course and research training offerings pertaining to its mission. A bi-monthly seminar series will also feature speakers with research interests covering the broad pharmaceutical oncology landscape.